Responses
Correction
Correction: Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Compose a Response to This Article
Other responses
No responses have been published for this article.